Pharmaceuticals: Accelerating Discovery with Generative AI Strategy
"In the U.S., around 15 million adults used generative AI as their primary tool for online search in 2024, with projections growing through 2028.” - Source: Statista
By the Numbers
What was the challenge?
Generative AI is revolutionizing the way users discover information, growing 165 times faster than organic search traffic since January 2024. Sloane, in collaboration with the in-house team, advanced an opportunity to integrate a generative engine strategy for a leading pharmaceutical company’s GLP-1 phase II data launch.
What was the approach?
By planning for generative engine platforms like ChatGPT, Perplexity, and Copilot, the team developed a launch approach optimized for generative engines, identifying new media targets with strong influence.
The team conducted a comprehensive analysis of drug visibility across AI platforms, benchmarked performance against competitors, and tracked key metrics such as manufacturer reputation, clinical trial results, and treatment efficacy.
What were the results?
A 79% rise in visibility score, a 78% increase in share-of-voice, and a significant boost in relevance across critical content categories post-announcement.
